Utilization Pattern for Eculizumab Among Children With Hemolytic Uremic Syndrome.
Ontology highlight
ABSTRACT: Background: Hemolytic uremic syndrome (HUS) is a complex disease with multi-organ involvement. Eculizumab therapy is recommended for treatment of complement mediated hemolytic uremic syndrome (cHUS). However, there are few studies evaluating eculizumab therapy among children with HUS. The primary objectives of the study were to describe and identify factors associated with eculizumab therapy in children with HUS. Design/Methods: This large, retrospective, multi-center, cohort study used the Pediatric Health Information System (PHIS) database to identify the index HUS-related hospitalization among patients ≤18 years of age from September 23, 2011 (Food and Drug Administration approval date of eculizumab) through December 31, 2018. Multivariate analysis was used to identify ind
SUBMITTER: Ranabothu S
PROVIDER: S-EPMC8523981 | biostudies-literature | 2021
REPOSITORIES: biostudies-literature
ACCESS DATA